CVS Health Corporation
93.47USD
-1.0100 (-1.07%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on CVS.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.65▼ | $1.71 | 5 | 1 |
| Next quarter | $1.24▼ | $1.33 | 0 | 6 |
| Current year | $8.04▲ | $7.44 | 3 | 2 |
| Next year | $8.54▲ | $8.41 | 4 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.85 | $2.58 | +0.73 (+39.4%) |
| 2026-03-31 | $2.21 | $2.57 | +0.36 (+16.5%) |
| 2025-12-31 | $1 | $1.09 | +0.09 (+9.4%) |
| 2025-09-30 | $1.36 | $1.6 | +0.24 (+17.9%) |
364 ratings from 42 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $119 $112 | Oct 12, 2026 |
| UBS | Maintained | Buy | $126 $118 | Sep 3, 2026 |
| Argus Research | Maintained | Buy | $104 $114 | Aug 19, 2026 |
| JP Morgan | Maintained | Overweight | $111 $118 | Aug 12, 2026 |
| UBS | Maintained | Buy | $122 $126 | Aug 6, 2026 |
| Evercore ISI Group | Maintained | Outperform | $130 $125 | Aug 6, 2026 |
| Barclays | Maintained | Overweight | $106 $108 | Aug 6, 2026 |
| UBS | Maintained | Buy | $115 $122 | Jul 25, 2026 |
| Truist Securities | Maintained | Buy | $108 $118 | Jul 14, 2026 |
| Wells Fargo | Maintained | Overweight | $103 $123 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $107 $113 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $100 $110 | Jul 7, 2026 |
| B of A Securities | Maintained | Buy | $100 $110 | Jun 23, 2026 |
| Mizuho | Maintained | Outperform | $110 $115 | Jun 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $106 $111 | Jun 4, 2026 |
| Truist Securities | Maintained | Buy | $102 $108 | Jun 1, 2026 |
| Barclays | Maintained | Overweight | $101 $106 | May 26, 2026 |
| Mizuho | Maintained | Outperform | $102 $110 | May 20, 2026 |
| Morgan Stanley | Maintained | Overweight | $93 $106 | May 14, 2026 |
| Bernstein | Maintained | Outperform | $94 $106 | May 13, 2026 |
| JP Morgan | Maintained | Overweight | $101 $111 | May 12, 2026 |
| TD Cowen | Maintained | Buy | $105 $110 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $102 $103 | May 8, 2026 |
| UBS | Maintained | Buy | $97 $100 | May 7, 2026 |
| RBC Capital | Maintained | Outperform | $93 $107 | May 7, 2026 |
67 filings from 24 insiders · 6 buy / 2 sell over 6m
Officers and directors of CVS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ROBBINS LARRYDirector | Sellindirect | 3.37M | $93.45 | $317.47M | May 21, 2026 |
| BALSER JEFFREY R M.D., PH.D.Director | Grant | 2.1k | $97.15 | $200k | May 14, 2026 |
| SANSONE GUY PDirector | Grant | 1.4k | $97.15 | $141k | May 14, 2026 |
| BROWN C DAVID IIDirector | Grant | 1.5k | $97.15 | $150k | May 14, 2026 |
| AGUIRRE FERNANDODirector | Grant | 1.6k | $97.15 | $152k | May 14, 2026 |
| NORWALK LESLIE VDirector | Grant | 1.4k | $97.15 | $141k | May 14, 2026 |
| KIRBY JOHN SCOTTDirector | Grant | 1.4k | $97.15 | $141k | May 14, 2026 |
| MANDADI TILAKOfficer | Sell | 69.6k | $89.58 | $6.23M | May 8, 2026 |
| COMPTON-PHILLIPS AMYOfficer | Grant | 5.6k | $71.82 | $400k | Mar 31, 2026 |
| MANDADI TILAKOfficer | Grant | 22.3k | $71.82 | $1.60M | Mar 31, 2026 |
| SHAH PREM SOfficer | Grant | 25.1k | $71.82 | $1.80M | Mar 31, 2026 |
| CLARK JAMES DAVIDOfficer | Grant | 11.1k | $71.82 | $800k | Mar 31, 2026 |
| NEWMAN BRIANChief Financial Officer | Grant | 19.5k | $71.82 | $1.40M | Mar 31, 2026 |
| JOYNER JOHN DAVIDChief Executive Officer | Grant | 86.3k | $71.82 | $6.20M | Mar 31, 2026 |
| NELSON STEVEN HOfficer | Grant | 22.3k | $71.82 | $1.60M | Mar 31, 2026 |
| KHICHI SAMRAT SGeneral Counsel | Grant | 12.5k | $71.82 | $900k | Mar 31, 2026 |
| CAPOZZI HEIDI BOfficer | Grant | 10.0k | $71.82 | $720k | Mar 31, 2026 |
| GALLINA JOHN EDirector | Grant | 582 | $71.86 | $42k | Mar 19, 2026 |
| SHULMAN DOUGLAS HDirector | Grant | 1.7k | $76.04 | $126k | Nov 20, 2025 |
| BALSER JEFFREY R M.D., PH.D.Director | Grant | 1.8k | $76.04 | $135k | Nov 20, 2025 |
No analyst notes on CVS yet.
Analyst Ratings
25 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 7 | 18 | 2 | 0 | 0 | Buy1.81 |
| 1 mo ago | 7 | 18 | 2 | 0 | 0 | Buy1.81 |
| 2 mo ago | 6 | 18 | 3 | 0 | 0 | Buy1.89 |
| 3 mo ago | 6 | 18 | 4 | 0 | 0 | Buy1.93 |
Members whose judged calls on CVS have played out most reliably.
No settled calls on CVS yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice